InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,663.20
(
0.13%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
83.92
(
-0.04%
)
Bitcoin
62,949.47
(
-0.16%
)
Post# of 251777
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 44
Posts 4535
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: pollyvonwog post# 188272

Friday, 03/06/2015 10:55:10 AM

Friday, March 06, 2015 10:55:10 AM

Post# of 251777
agree other issues w the report as well - citing competitive concerns for example when after MRK there isn't anyone close (assuming BMy bows out), GILD pan genotypic drug won't effect the GT1 landscape (and may be perceive as inferior to harvoni - as evidenced by the 8 week data), the fact ABBV next gen is pan genotypic which can open up the non-GT1 market to them, and most of all there just isn't much room for improvement any more - is going from 8 to 6 weeks going to mean much?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up